Roger - ROG STOCK NEWS

Rogers (NYSE:ROG) has announced it will release its first quarter 2025 financial results on April 29, 2025, after market close. The company will host a conference call at 5:00 pm ET on the same day.

The earnings call will be led by Colin Gouveia, President and CEO, alongside Laura Russell, Senior Vice President and CFO. Investors can access the live webcast and accompanying slide presentation through Rogers' Investor Relations website at rogerscorp.com/investors, where a replay will also be available.

Rogers is a global leader in engineered materials, specializing in solutions for EV/HEV, automotive safety, radar systems, mobile devices, renewable energy, wireless infrastructure, and energy-efficient motor drives.

Rogers (NYSE:ROG) reported Q4 2024 financial results with net sales of $192.2 million, representing an 8.6% decrease from the previous quarter. The decline was attributed to lower sales in both AES and EMS business units, particularly in wireless infrastructure and industrial sectors.

Gross margin decreased to 32.1% from 35.2% in the prior quarter due to lower volume and unfavorable product mix. GAAP operating margin fell to -2.6% from 6.9%, while adjusted operating margin decreased by 700 basis points to 4.7%. The company reported GAAP earnings per diluted share of $(0.03) compared to $0.58 in the previous quarter, and adjusted earnings of $0.46 per diluted share versus $0.98.

The company ended the quarter with $159.8 million in cash and cash equivalents, an increase of $13.4 million. Net cash provided by operating activities was $33.7 million, with capital expenditures of $15.4 million.

Rogers (NYSE:ROG) has announced it will release its fourth quarter and full year 2024 financial results on February 19, 2025, after market close. The company will host a conference call at 5:00 pm ET on the same day.

The earnings call will be led by Colin Gouveia, President and CEO, alongside Laura Russell, Senior VP and CFO. Investors can access the live webcast and related presentation materials through Rogers' Investor Relations website, where a replay will also be available.

Rogers is a global leader in engineered materials, specializing in solutions for EV/HEV, automotive safety, radar systems, mobile devices, renewable energy, wireless infrastructure, and industrial equipment.

Roche (RHHBY) has received FDA 510(k) clearance for its VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail, a groundbreaking test for diagnosing B-cell lymphoma. This follows its CE Mark approval in June 2024. The test is the first clinically approved in-situ hybridisation (ISH) test capable of assessing all B-cell lymphoma subtypes.

The highly-sensitive test helps distinguish between B-cell cancer and normal immune responses, enabling faster diagnosis and treatment initiation. It can evaluate over 60 B-cell lymphoma subtypes and plasma cell neoplasms on a single tissue slide, working with small biopsies and formalin-fixed tissue. This reduces the need for fresh tissue samples and additional biopsies.

B-cell lymphoma represents about 85% of non-Hodgkin lymphoma (NHL) cases, with NHL being one of the most common cancers in the US, accounting for 4% of all cancer cases and causing over 80,000 deaths annually.

Rogers (NYSE: ROG) has announced the appointment of Woon Keat Moh as an independent member of its Board of Directors, effective January 1, 2025. This addition will expand the Board to nine members, with eight being independent directors. Moh brings nearly 30 years of experience in the specialty materials industry, including significant leadership roles in both Asia and North America. Board Chair Peter Wallace emphasized that Moh's extensive experience in leading global businesses will contribute to Rogers' strategy and shareholder value creation.

Rogers (NYSE: ROG) has appointed Laura Russell as Senior Vice President, Chief Financial Officer and Treasurer, effective December 10. Russell, 49, has been serving as interim CFO since August 2024, following her initial role as Vice President of Finance which she assumed upon joining the company in September 2023.

Prior to Rogers, Russell held key positions including Vice President of Finance, Operations at Wolfspeed (2021-2023) and Vice President of Finance for NXP Semiconductors' Radio Products business (2015-2021). She also worked at Motorola and Freescale Semiconductors from 1997 to 2015. Russell holds a BA in Business Economics from the University of the West of Scotland and is a member of the Chartered Institute of Management Accountants.

Roche has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry companion diagnostic test in Europe for identifying epithelial ovarian cancer patients eligible for ELAHERE treatment. The test detects folate receptor 1 protein, expressed in about 90% of ovarian carcinomas. This certification follows an early exemption approval in Germany and Austria earlier this year. The test aims to enable more precise treatment decisions for ovarian cancer, which causes 46,232 deaths annually in Europe and is the eighth leading cause of cancer death in women worldwide.

Rogers (NYSE:ROG) reported mixed Q3 2024 results with net sales of $210.3 million, down 1.8% from Q2. Despite lower sales, earnings exceeded guidance due to operational improvements and expense management. GAAP operating margin improved to 6.9% from 5.3%, while adjusted earnings reached $0.98 per diluted share. The company faced softer EV/HEV demand and lower seasonal peak in portable electronics. Looking ahead, Q4 sales are expected to decline due to seasonality and customer inventory management. The company highlighted its expansion with a new power substrate factory in China targeting EV/HEV, renewable energy, and industrial markets.

Roche has received FDA approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first companion diagnostic to identify patients with gastric and gastroesophageal junction (GEJ) cancer eligible for targeted treatment with VYLOY. This immunohistochemistry (IHC) assay helps determine CLDN18 protein expression in tumors, enabling clinicians to identify patients who may benefit from Astellas' targeted therapy VYLOY (zolbetuximab).

The assay addresses an unmet medical need by helping predict the likelihood of response to targeted therapy in gastric and GEJ cancers. CLDN18.2 is an emerging biomarker in these cancers. This approval aligns with current guidelines recommending biomarker use to guide therapeutic decision-making in gastric/GEJ cancer.

Gastric cancer is the fifth most common cancer and fourth leading cause of cancer deaths worldwide. In the U.S., 62% of gastric/GEJ cancer cases are advanced at initial diagnosis, with a five-year overall survival rate of only 6%.